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Abstract. Downstream of tyrosine kinase 7 transcript variant 1 
(DOK7V1) is a docking protein mediating signal transduction 
between receptors and intracellular downstream molecules. 
Our previous study indicated that DOK7V1 was decreased 
in lung cancer and its lower expression was associated with 
a decreased survival rate. The 5-year overall survival rate for 
patients with lung cancer was 20.2 and 18.6% for high and 
low DOK7 expression, respectively; the 5-year disease-free 
survival rate for patients with lung cancer was 14.3 and 16.9% 
for high and low DOK7 expression, respectively. DOK7V1 
inhibited proliferation and migration, but enhanced adhe-
sion, of lung cancer cells. In the present study, the effect of 
DOK7V1 and its domains [pleckstrin homology (PH) and 
phosphotyrosine-binding (PTB) domain] on the malignant 
phenotype and associated signaling pathway in lung cancer 
cells was investigated. The results indicated that truncation 
of DOK7V1 domains (DOK7V1Δ-PH and DOK7V1Δ-PTB) 
inhibited the proliferation and migration of lung cancer 
cells which exhibited the same trend as DOK7V1, whereas 
DOK7V1Δ-PH and DOK7V1Δ-PTB exhibited different 
functions from those of DOK7V1 in cell matrix adhesion. 
Consistently, DOK7V1 overexpression in lung cancer cells 
suppressed the phosphoinositide 3-kinase (PI3K)/protein 
kinase B (AKT)/mammalian target of rapamycin (mTOR) 
signaling pathways, but activated the focal adhesion kinase 
(FAK)/paxillin signaling pathway. Taken together, these 
results indicate that DOK7V1 may inhibit proliferation and 
migration via negatively regulating the PI3K/AKT/mTOR 
signaling pathway, and increase adhesion by upregulating the 
FAK/paxillin signaling pathway in lung cancer cells.
Introduction
Lung cancer remains the leading cause of cancer mortality 
and has become an increasingly serious public health burden 
globally (1). Lung cancer is categorized into small cell lung 
cancer (SCLC) and non-SCLC (NSCLC) following patho-
logical pattern. NSCLC accounts for ~80% of all lung cancer 
cases, including squamous cell carcinoma, adenocarcinoma, 
large cell carcinoma and adenosquamous cell carcinoma (2). 
NSCLC is often diagnosed at an advanced stage and the 
5-year survival rate remains ~15% (3). Therefore, there is an 
urgent requirement to identify and screen for tumor-associated 
genes, further investigate the molecular mechanisms of 
NSCLC tumorigenesis and development, and identify novel 
biomarkers for early diagnosis and therapeutic targets of 
NSCLC. Tumor-associated genes rely on diverse signaling 
pathways to influence the proliferation, migration and invasion 
of tumor cells, and subsequently disseminate from primary 
tumors to metastasize through lymphatic and blood vessels. 
Understanding the molecular mechanisms underlying tumor 
metastasis has a critical significance in formulating treat-
ment and early diagnosis. Receptor tyrosine kinases (RTKs) 
serve a vital function in regulating cellular process, including 
cell migration, proliferation, differentiation, survival and 
cell cycle regulation (4,5). Deregulation of RTKs includes 
chromosomal translocations, autocrine activation, overexpres-
sion of RTKs or gain-of-function mutations which occurs in 
cancer (6). The downstream of tyrosine kinase (DOK) protein 
family consists of seven members, mediating intracellular 
signaling transduction downstream of RTKs (7-9). DOK 
proteins share a topology domain characterized by a central 
phosphotyrosine-binding (PTB) domain, an N-terminal 
pleckstrin homology (PH) domain and Src homology 2 target 
motifs in the C-terminus (7,10). On the basis of their location, 
DOK proteins are divided into three subgroups: DOKs 1-3 
are mainly expressed in hematopoietic tissues (11), DOKs 4-6 
are primarily present within the nervous system (12,13), and 
DOK7 is predominantly in skeletal muscle and the heart, which 
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exhibits a distinct function compared with other members (14). 
Aberrant expression of DOK proteins has been identified in 
multiple malignancies. DOKs 1-3 co-operatively suppress 
aggressive histiocytic sarcoma (11). DOK2 was regarded as 
a biomarker of patients with gastric cancer with poor prog-
nosis (15,16). In a mouse model, deletion of DOKs 1-3 resulted 
in abnormal proliferation of bronchoalveolar stem cells and 
alveolar type II cells, which subsequently progressed to lung 
cancer (7). In addition, a decreased expression level of DOK2 
was observed in human lung cancer tissues, and forced DOK2 
overexpression repressed proliferation of lung cancer cells (7).
DOK7, as a non-catalytic adaptor protein, is essential for 
the activation of the tyrosine kinase muscle‑specific kinase 
(MuSK) and acetylcholine receptor clustering, which are 
indispensable for neuromuscular junctions (17,18). The func-
tion of DOK7 in cancer was revealed gradually. Demethylation 
of DOK7 decreased the proliferation and invasion of esopha-
geal squamous cell carcinoma cells (19). The PTB domain is 
the region through which DOK7 interacts with the juxtamem-
brane region of MuSK, although the PTB and PH domains 
are required for the activation of MuSK (18,20,21). The PH 
domain consists of ~120 amino acids, mediating intracellular 
and extracellular signaling, also acting as important constitu-
ents of the cytoskeleton (22-24). PTB was also able to contact 
the cell membrane, and regulate intracellular and extracellular 
signaling. For example, PH and PTB domains of DOK4 are 
required for DOK4 localization at the membrane (10). The 
DOK1 PH domain appears to be required for tyrosine phos-
phorylation of the protein and its normal localization to a 
subcellular membrane component (10).
In our previous study, we identified that DOK7 transcripts 
were decreased in lung cancer, and the lower DOK7 level was 
associated with poorer overall survival and progression-free 
survival (25). Overexpression of the DOK 7 transcript 
variant 1 (DOK7V1) limited the proliferation and migration, 
but enhanced the adhesion to the extracellular matrix, of 
lung cancer cells (25). However, the underlying molecular 
mechanism of DOK7V1 and the functions of its domains in 
lung cancer cells remain unknown. Therefore, the aim of the 
present study was to investigate the functions of its domains 
and the molecular mechanism underlying its involvement in 
lung cancer cells.
Materials and methods
Cell culture. Lung cancer A549, SKMES-1 and H3122 cell 
lines were purchased from the American Type Culture 
Collection (Manassas, VA, USA). A549 and SKMES-1 
cells were routinely cultured in Dulbecco's modified Eagle's 
medium (Thermo Fisher Scientific, Inc., Waltham, MA, 
USA) and H3122 cells were cultured in RPMI-1640 medium 
(Thermo Fisher Scientific, Inc.), supplemented with 10% fetal 
bovine serum (Shanghai ExCellBio, Inc., Shanghai, China), 
in an incubator at 37˚C with a 95% humidified atmosphere 
containing 5% CO2.
Construction of DOK7V1 plasmid and transfection. 
DOK7V1-Flag and pEnter (Vector) plasmids were purchased 
from Vigene Biosciences, Inc. (Rockville, MD, USA). 
DOK7V1Δ-PH and DOK7V1Δ-PTB were constructed using a 
Q5® Site-Directed Mutagenesis kit (Without Competent Cells) 
(New England BioLabs, Inc., Ipswich, MA, USA). Purified 
DOK7V1 and control plasmids were transfected into A549 and 
SKMES-1 cells using an Easyject Plus electroporator (EquiBio 
Ltd., Altrincham, UK). H3122 cells were transfected with 
DOK7V1, DOK7V1Δ-PH and DOK7V1Δ-PTB, respectively, 
using Neofect™ DNA transfection reagent (Neofectbiotech 
Co., Ltd., Beijing, China).
RNA isolation and reverse transcription‑polymerase chain 
reaction (RT‑PCR). Total RNA was isolated from A549, 
SKMES-1 and H3122 cells using TRIzol® reagent (Invitrogen; 
Thermo Fisher Scientific, Inc.). cDNA was generated from each 
1 µg RNA sample using a QuantiTect Reverse Transcription 
kit (Qiagen GmbH, Hilden, Germany), according to the 
manufacturer's protocol. PCR was performed as described 
previously (26) with the following primer sequences: 
DOK7, 5'-ACTGGGCTGGCGTCTTCTTCC-3' (forward) 
and 5'-TCGGACGATGCAGTCGAACAG-3' (reverse); and 
GAPDH, 5'-GGCTGCTTTTAACTCTGGTA-3' (forward) and 
5'-GACTGTGGTCATGAGTCCTT-3' (reverse).
Western blot analysis. Cells were collected and lysed using 
Radioimmunoprecipitation Assay Lysis and Extraction Buffer 
(Thermo Fisher Scientific, Inc.), followed by centrifugation at 
13,000 x g for 15 min at 4˚C. Total protein concentrations in 
the supernatant were determined using a DC Protein Assay 
kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and 
an ELx800 spectrophotometer (Bio-Tek Instruments, Inc., 
Winooski, VT, USA). Equal amounts (30 µg) of protein 
samples were separated by SDS-PAGE (10% gel) and 
blotted onto a nitrocellulose membrane. The membrane was 
blocked using 5% skimmed milk in Tris-buffered saline for 
1 h at room temperature. Proteins were then probed using 
anti-human FLAG (1:1,000; cat. no. F3040; Sigma; Merck 
KGaA, Darmstadt, Germany), anti-DOK7 antibody (1:1,000; 
cat. no. ab75049; Abcam, Cambridge, MA, USA), anti-protein 
kinase B (AKT) antibody (1:1,000; cat. no. 2920; Cell 
Signaling Technology, Inc., Danvers, MA, USA), anti-phospho 
(p)-AKT (1:1,000; cat. no. 4051; Cell Signaling Technology, 
Inc.), anti-phosphoinositide 3-kinase (PI3K) antibody (1:500; 
cat. no. sc-365290; Santa Cruz Biotechnology, Inc., Dallas, 
TX, USA), anti-p-PI3K antibody (1:500; cat. no. sc-374534; 
Santa Cruz Biotechnology, Inc.), anti-mammalian target of 
rapamycin (mTOR) antibody (1:1,000; cat. no. ab2732; Abcam), 
anti-p-mTOR antibody (1:1,000; cat. no. 2971; Cell Signaling 
Technology, Inc.), anti-Rho-associated protein kinase (Rock) 
antibody (1:500; cat. no. sc-17794; Santa Cruz Biotechnology, 
Inc.), anti-p-Rock antibody (1:1,000; cat. no. ab2732; Abcam), 
anti-focal adhesion kinase (FAK) antibody (1:500; cat. 
no. sc-1688; Santa Cruz Biotechnology, Inc.), anti-p-FAK 
antibody (1:500; cat. no. sc-11766; Santa Cruz Biotechnology, 
Inc.), anti-paxillin antibody (1:500; cat. no. sc-365174; 
Santa Cruz Biotechnology, Inc.), anti-p-paxillin antibody 
(1:500; cat. no. sc-365020; Santa Cruz Biotechnology, Inc.), 
anti-human GAPDH antibody (1:500; cat. no. sc-47724; Santa 
Cruz Biotechnology, Inc.) and corresponding horseradish 
peroxidase (HRP)-conjugated goat anti-rabbit and goat 
anti-mouse immunoglobulin G secondary antibodies (1:3,000; 
cat. nos. ZB-2301M and ZB-2305; OriGene Technologies, Inc., 
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Beijing, China), respectively. Protein bands were visualized 
and analyzed using Luminata Forte western blot HRP substrate 
(Merck KGaA) and a UV imager (Uvitec, Inc., Cambridge, 
UK).
Immunofluorescence. Cells on glass coverslips were rinsed with 
PBS three times, and then fixed with 4% paraformaldehyde for 
20 min at room temperature. Anti-human FLAG was diluted 
1:1,000 in blocking buffer (1% bovine serum albumin in PBS), 
prior to adding to the coverslips and incubating for 1 h at room 
temperature. Following three washes with PBS, the coverslips 
were incubated using Alexa Fluor® 488-conjugated secondary 
antibodies (1:100; cat. no. A‑21205; Thermo Fisher Scientific, 
Inc.) for 45 min at room temperature. Following three further 
washes with PBS, nuclei were stained with DAPI (1:500,000; 
cat. no. D‑1306; Thermo Fisher Scientific, Inc.) for 2 min at 
room temperature, followed by three further washes with PBS. 
The coverslips were mounted on glass slides and incubated 
at room temperature overnight. Immunofluorescence images 
were visualized using a confocal microscopy system (Leica 
TCS SP8; Leica Microsystems GmbH, Wetzlar, Germany) 
with a 63X oil-immersion objective.
In vitro cell proliferation assays. A total of 3,000 cells in 
200 µl culture medium was added to each well of a 96-well 
plate. A total of five plates were used to obtain cell density read-
ings following incubation at 37˚C for up to 4 days. Following 
incubation, the medium was removed and 100 µl 10% Cell 
Counting Kit-8 (Dojindo Molecular Technologies, Inc., 
Kumamoto, Japan) was added for 1 h at 37˚C. Subsequently, 
the absorbance was determined at a wavelength of 450 nm 
using a spectrophotometer (BioTek Instruments, Inc.).
In vitro tumor cell migration assay. Cells (1x106 cells/well) 
were seeded in a 6-well plate and cultured in an incubator 
at 37˚C overnight. The cell monolayer was scratched with a 
200‑µl pipette tip to create an artificial wound prior to washing 
twice with PBS to remove floating cells. The migration of cells 
was monitored and recorded every 6 h using an inverted light 
microscope at x10 and x20 magnification for 24 h. The wound 
distance was determined and analyzed using ImageJ software 
(version 1.62; National Institutes of Health, Bethesda, MD, 
USA).
In vitro tumor cell Matrigel adhesion assay. A 96-well plate 
was coated with 5 µg Matrigel/100 µl/well and air-dried 
overnight at room temperature. Following rehydration, 
20,000 cells/200 µl/well were seeded into each well for 
40 min. Following incubation, medium was removed and 
the plate was washed three times with PBS to remove the 
non‑adherent cells. Adherent cells were fixed with 4% form-
aldehyde for 30 min prior to being stained with 0.5% crystal 
violet solution for 10 min at room temperature. Subsequently, 
crystal violet was dissolved in 10% acetic acid and the absor-
bance at 570 nm was determined using a spectrophotometer 
(BioTek Instruments, Inc.).
Gene set enrichment analysis (GSEA). The association 
between biological processes/pathway, phenotypes and DOK7 
expression level was analyzed using the GSEA program 
(version 2.2; www.broad.mit.edu/gsea). Samples from The 
Cancer Genome Atlas (TCGA) datasets were separated into 
high or low DOK7 expression groups using the median as the 
cut-off. GSEA was used to calculate a pathway Enrichment 
Score that assessed whether genes from a predefined gene set 
Figure 1. Expression level of DOK7V1 in lung cancer cell lines. (A) Expression of DOK7V1 in A549, SKMES-1 and H3122 cells was determined using RT-PCR 
analysis. Following transfection, respective overexpression of DOK7V1 in A549 and SKMES-1 cells were determined using (B) RT-PCR and (C) western 
blot analysis. DOK7V1, downstream of tyrosine kinase 7 transcript variant 1; RT-PCR, reverse transcription-polymerase chain reaction; WB, western blot.
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of PI3K/AKT/mTOR and FAK/paxillin signaling pathways 
were enriched among the high- (or low-) ranked genes or 
distributed randomly. Default settings were utilized when 
using software applications. Significance was determined by 
permutation analysis (1,000 permutations) and calculation of 
the false discovery rate (FDR). A gene set was considered to 
be significantly enriched when the FDR score was <0.05.
Statistical analysis. Data are presented as the mean ± standard 
deviation. Experimental procedures were repeated indepen-
dently at least three times. Statistical analysis was performed 
using a two-sided Student's t-test for two-group comparisons 
and by one-way ANOVA, followed by a Bonferroni post hoc 
test, for multiple group comparisons. All statistical analyses 
were performed using Prism (version 5; GraphPad Software, 
Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a 
statistically significant difference.
Results
Overexpression of DOK7V1 has an inhibitory effect on 
proliferation and migration, but a positive effect on adhesion 
in lung cancer cells. To select the optimal cell lines for further 
investigation, the expression of DOK7V1 in A549, SKMES-1 
and H3122 cells was determined using RT-PCR analysis. The 
stable transfection of DOK7V1 in the lung cancer cell lines 
was verified by RT‑PCR and western blot analysis (Fig. 1). To 
further confirm the effect of DOK7V1 on malignant phenotypes 
of lung cancer cells, the experiments were performed in A549 
and SKMES-1 cells. The results indicated that overexpression 
of DOK7V1 significantly decreased the proliferation and 
migration, but significantly increased the adhesion, of A549 
and SKMES-1 cells (Fig. 2).
PH domain and PTB domain determined the distribution of 
DOK7V1 in membrane and cytoplasm. DOK7V1 contains 
two functional domains: A PH domain and a PTB domain. 
To investigate the structural determinant regulating the 
intracellular distribution and expression of DOK7V1, as 
well as the biological function, two DOK7V1 truncated 
fragments were constructed based on the wild-type protein, 
DOK7V1Δ-PH and DOK7V1Δ-PTB (Fig. 3A). The immu-
nofluorescence imaging results indicated that wild-type 
DOK7V1 was located and expressed in the membrane and 
cytoplasm. The truncated versions of DOK7V1 without the 
two functional domains led to a shift in the localization 
of DOK7V1 protein from the cytoplasm to be perinuclear 
(Fig. 3B). The results indicated that these two functional 
domains determined the distribution of DOK7V1 in the 
membrane and cytoplasm, which may influence the function 
of DOK7V1 in lung cancer cells.
Effect of the PH domain and PTB domain of DOK7V1 on the 
proliferation, migration and adhesion of lung cancer cells. 
Figure 2. Effect of forced DOK7V1 expression on biological functions in lung cancer cells. (A) Increased DOK7V1 expression inhibited the in vitro prolifera-
tion of A549 and SKMES-1 cells. (B) DOK7V1 overexpression in A549 and SKMES-1 cells exhibited an inhibitory effect on cell motility. (C) Expression of 
DOK7V1 increased cell-matrix adhesion of lung cancer cells. Results are representative of three independent experiments for each function assay. *P<0.05, 
**P<0.01, ***P<0.001 vs. vector control. DOK7V1, downstream of tyrosine kinase 7 transcript variant 1; OD, optical density.
INTERNATIONAL JOURNAL OF ONCOLOGY  54:  381-389,  2019 385
To further assess the biological function of DOK7V1Δ-PH 
and DOK7V1Δ-PTB, these truncated versions were stably 
transfected into H3122 cells and their expression was deter-
mined by western blotting. DOK7V1, DOK7V1Δ-PH and 
DOK7V1Δ‑PTB were identified to exhibit increased expression 
in stably transfected cells compared with in the corresponding 
control cells (Fig. 4A). It was identified that cell proliferation 
was significantly decreased from the third day, and migration 
was significantly decreased at 18 h, in cells singly overex-
pressing DOK7V1Δ-PH and DOK7V1Δ-PTB compared 
with vector control cells, which exhibited the same trend as 
DOK7V1 (Fig. 4B and 4C). The adhesion assay revealed an 
increased rate in DOK7V1-overexpressing cells compared 
with the control group; however, the DOK7V1Δ-PH and 
DOK7V1Δ-PTB truncated versions lost the tumor-promoting 
effects identified in DOK7V1 (Fig. 4D).
Figure 3. PH and PTB domains determine the distribution of DOK7V1 in the nuclear membrane and cytoplasm. (A) Schematic representation of DOK7V1 
and its truncated fragments. (B) The cytoplasm was stained green and the nucleus was stained blue. Merged images are presented. The truncated versions 
of DOK7V1 without the PH or PTB functional domain appeared to have an effect on the localization of the protein. Intensive staining may be observed sur-
rounding the nucleus. PH, pleckstrin homology; PTB, phosphotyrosine-binding; DOK7V1, downstream of tyrosine kinase 7 transcript variant 1.
Figure 4. Effect of PH domain and PTB domain of DOK7V1 on lung cancer cell proliferation, migration and adhesion. (A) Wild-type and two truncated 
versions of DOK7V1 were stably transfected into H3122 cells and detected with an anti-FLAG antibody. (B) DOK7V1Δ-PH and DOK7V1Δ-PTB decreased 
the proliferation and migration (C), which was similar to that with DOK7V1. (D) DOK7V1Δ-PH and DOK7V1Δ-PTB truncated versions lost the adhe-
sion-promoter effect observed in DOK7V1. *P<0.05, ***P<0.001 vs. vector control. PH, pleckstrin homology; PTB, phosphotyrosine‑binding domain; DOK7V1, 
downstream of tyrosine kinase 7 transcript variant 1.
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No differences exist between the two truncated versions and 
DOK7V1 in inhibiting PI3K/AKT/mTOR signal pathway 
phosphorylation. To further study the signal pathways in 
which DOK7V1 is involved, the protein levels and phos-
phorylation levels of AKT, PI3K, mTOR and Rock in A549 
cells were determined. Decreased levels of AKT, PI3K and 
Rock phosphorylation were observed in A549 cells with 
DOK7V1 overexpression, whereas the total AKT, PI3K and 
Rock protein levels were similar in comparison with their 
corresponding controls (Fig. 5A). mTOR phosphorylation 
and the total mTOR protein levels were decreased in A549 
cell lines with DOK7V1 overexpression (Fig. 5A). The AKT 
phosphorylation status was investigated in H3122 cells 
transfected with various DOK7V1 constructs. Wild-type 
DOK7V1 overexpression significantly arrested AKT activa-
tion, and this inhibition was similar in cells expressing the 
DOK7V1Δ-PH and DOK7V1Δ-PTB truncated versions 
(Fig. 5B). Taken together, these results indicated that the two 
truncated version of DOK7V1 did not eliminate the inhibi-
tory function of DOK7V1 in activating AKT.
DOK7V1Δ‑PH and DOK7V1Δ‑PTB eliminate the activating 
effect of DOK7V1 on FAK and paxillin. FAK and paxillin 
are important proteins in focal adhesion, by connecting the 
cytoskeleton to the extracellular matrix. In view of DOK7V1 
increasing the adhesion of lung cancer cells, the changes in 
associated factors in the FAK/paxillin signaling pathway were 
investigated. The overexpression of DOK7V1 significantly 
increased FAK and paxillin phosphorylation (Fig. 6A) in 
A549 cells; however, this influence was partially eliminated in 
H3122 cells expressing DOK7V1Δ-PH and DOK7V1Δ-PTB 
in cells (Fig. 6B). These results indicated that the PH domain 
and PTB domain serve a key function in regulating cell adhe-
sion.
DOK7 overexpression is negatively associated with activation 
of the PI3K/AKT/mTOR signaling pathway and is positively 
associated with adherent ability. To further analyze the 
function of DOK7 expression in PI3K/AKT/mTOR signaling 
in lung cancer, GSEA was performed using a lung cancer 
dataset from TCGA. The lung cancer samples were separated 
according to the median DOK7 level in the specimens into 
high or low expression groups. Enrichment plots of GSEA 
demonstrated that the gene set of PI3K/AKT/mTOR signaling 
was primarily enriched in the low DOK7 expression group 
(Fig. 7A). The association between DOK7 expression and 
activation of FAK/paxillin signaling in lung cancer was identi-
fied using GSEA. As presented in Fig. 7B, the gene signatures 
of adhesion, which emphasized the importance of FAK in 
its description, were enriched in patients with high DOK7 
expression. These results further suggested that, in lung cancer 
samples, DOK7 expression was negatively associated with 
PI3K/AKT/mTOR signaling activation and is positively asso-
ciated with activation of the FAK/paxillin signaling pathway.
Discussion
In our previous study, we preliminarily studied the function 
of DOK7V1 in lung cancer cells and the association with the 
prognosis of patients with lung cancer (25). In the present 
study, the focus was on the mechanisms and functions of 
DOK7V1 and its domains in the lung cancer cells. The results 
of the present study suggested a hitherto unknown regulatory 
mechanism of DOK7V1 in lung cancer cells, which influences 
Figure 5. No differences exist between the two truncated versions and DOK7V1 in inhibiting PI3K/AKT/mTOR signal pathway phosphorylation. 
(A) Immunoblotting was performed using anti-p-AKT and anti-AKT, p-mTOR and mTOR, p-PI3K and PI3K, Rock and p-Rock. GAPDH, AKT and mTOR 
were separated in the same lane of the gel. (B) DOK7V1Δ-PH and DOK7V1Δ-PTB did not result in the loss-of-function of the DOK7V1-mediated inhibition of 
AKT activation. DOK7V1, downstream of tyrosine kinase 7 transcript variant 1; PI3K, phosphoinositide 3-kinase; AKT, protein kinase B; mTOR, mammalian 
target of rapamycin; p-, phospho-; Rock, Rho-associated protein kinase; PH, pleckstrin homology; PTB, phosphotyrosine-binding; Wt, wild-type (cells without 
treatment).
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cell adhesion, but not the proliferation and migration by its 
primary domain.
The functions of the DOK protein family in lung cancer 
have gradually been identified. DOKs 1‑3 have been identified 
to be absent from or decreased in lung cancer (23). In mouse 
models, a lack of DOKs 1-3 promoted the proliferation of 
bronchoalveolar stem cells and alveolar type II cells, which 
resulted in the development of lung cancer, particularly in 
triple knockout mouse models (11). Decreased DOK2 levels 
were identified in primary lung adenocarcinomas and lymph 
node metastases, whereas no difference in expression of 
DOK1 and DOK3 was identified in lung cancer compared 
with normal tissues, although a decreased DOK3 level was 
observed in lymph node metastasis tissues when compared 
with its expression in primary tumor (7). DOK2 was identified 
as a tumor suppressor gene of lung cancer, since DOK2 was 
associated with epidermal growth factor receptor mutations 
to promote lung cancer (27). DOK7 was the primary focus in 
the present study. In breast cancer, DOK7 is downregulated 
owing to the hypermethylation of its CpG islands (22). The 
results of this study indicated that DOK proteins may serve an 
inhibitory function in cancer development, and gene deletion or 
hypermethylation of DOK proteins may occur in cancer cells. 
In addition, our previous study identified a lower expression 
level of DOK7 in lung cancer and DOK7V1 overexpression, 
resulting in a decrease in proliferation and migration, and an 
increase in adhesion in lung cancer cells (25). In the present 
study, the experiments in which DOK7V1 inhibited prolifera-
tion and migration, but promoted adhesion in other lung cancer 
cell lines were repeated to confirm the effect of DOK7V1 on 
the malignant phenotype. Furthermore, the change of invasion 
following transfection of lung cancer cells with DOK7V1 was 
investigated, but no difference between the test group and 
control group was identified.
DOK7V1 is a 1,515-residue protein, containing a PH 
domain, a PTB domain and C-terminal sites of tyrosine 
Figure 6. DOK7V1Δ-PH and DOK7V1Δ-PTB eliminate the activating effect of DOK7V1 on FAK and paxillin activation. (A) The phosphorylation of 
FAK and paxillin were activated when DOK7V1 was overexpressed in A549 cells. GAPDH, FAK and paxillin were separated in the same lane of the gel. 
(B) DOK7V1Δ-PH and DOK7V1Δ-PTB led to the loss of function of the DOK7V1-mediated promotion of FAK and paxillin activation. DOK7V1, downstream 
of tyrosine kinase 7 transcript variant 1; PH, pleckstrin homology; PTB, phosphotyrosine-binding; FAK, focal adhesion kinase; p-, phospho-.
Figure 7. DOK7 expression is negatively associated with activation of the PI3K/AKT/mTOR signaling pathway, but is positively associated with activation 
of the FAK/paxillin signaling pathway. (A) DOK7 enrichment plots of gene expression signatures for the PI3K/AKT/mTOR signaling pathway according 
to DOK7 mRNA expression levels by gene set enrichment analysis of samples from The Cancer Genome Atlas. (B) The gene signatures of adhesion 
associated with FAK were enriched in patients with high DOK7 expression. DOK7, downstream of tyrosine kinase 7; PI3K, phosphoinositide 3-kinase; 
AKT, protein kinase B; mTOR, mammalian target of rapamycin; FAK, focal adhesion kinase; NES, normalized enrichment score; FDR, false discovery 
rate; EXP, expression.
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phosphorylation. DOK7 is a substrate of MuSK and also an 
activator of its kinase activity, and is therefore an important 
protein for forming the vertebrate neuromuscular junction, 
and may facilitate trans-autophosphorylation of the kinase 
activation loop via a dimeric arrangement of its PH and 
PTB domains (28). A truncation of the domains may lead to 
changes in protein localization. A recent study revealed that 
DOK7 bound to membranes containing phosphatidylinositol 
phosphates (PIPs) through PH domain binding, facilitating 
local clustering of PIP molecules in the bilayer (29). In the 
present study, the PH and PTB domains were identified to 
determine the localization of DOK7V1 in the membrane and 
cytoplasm, as revealed by the nuclear membrane distribution 
of PH- and PTB-truncated DOK7V1 proteins (DOK7V1Δ-PH 
and DOK7V1Δ-PTB). Does this change in location have an 
effect on the function of the protein? In the present study, in 
vitro functional experiments indicated that DOK7V1 over-
expression inhibited H3122 cell proliferation, motility and 
adhesion, and DOK7V1Δ-PH and DOK7V1Δ-PTB have the 
same effect on proliferation and motility as DOK7V1, but with 
the enhancement of adhesion eliminated.
Dysregulation of the PI3K/AKT/mTOR signaling pathway 
has been implicated in the cancerous migration, prolifera-
tion and poor prognosis of various types of cancer, including 
lung cancer (30-32). Tumor suppressor genes decreased the 
proliferation and migration of NSCLC by inhibiting the 
PI3K/AKT/mTOR signaling pathway (33). The in vitro results 
of the present study indicated that DOK7V1 inhibited the phos-
phorylation of AKT, PI3K, mTOR and ROCK in A549 cells. The 
two truncated versions of DOK7V1 also could not active AKT 
in H3122 cells. PI3K/AKT signaling appears to rely on DOK7 
in the cytoplasm or associated with the RTK. The weakened 
PI3K/AKT signaling may be caused by the retention of truncated 
DOK7V1 at the perinuclear area. Further analysis indicated that 
an increased level of DOK7V1 was negatively associated with 
the activation of PI3K/AKT/mTOR signaling. According to 
these results, we hypothesize that DOK7V1 overexpression may 
inhibit the proliferation and migration by suppressing the acti-
vation of PI3K/AKT/mTOR signaling pathway. However, a clear 
conclusion cannot be made. Investigation of whether DOK7V1 
decreases the proliferation and migration of lung cancer cells 
following inhibition of the PI3K/AKT/mTOR signaling pathway 
is required in future studies.
Hyperactivation of the FAK/paxillin signaling pathway 
was identified to be significantly associated with cell adhe-
sion (34-36). FAK and paxillin dynamics serve an essential 
function in regulating the adhesion of various cells (37). In the 
present study, an increased adhesion rate of cells overexpressing 
DOK7V1 compared with that of the control group was revealed; 
however, the DOK7V1Δ-PH and DOK7V1Δ-PTB truncated 
versions eliminated the tumor-promoting effects observed in 
DOK7V1. Conversely, FAK and paxillin were also weakened, 
which provides further evidence of the association between its 
location and function. Furthermore, it was confirmed that the 
gene signatures associated with FAK/paxillin signaling acti-
vation were enriched in patients with high DOK7 expression. 
These results further suggested that in lung cancer specimens, 
DOK7 expression was positively associated with activation 
of the FAK/paxillin signaling pathway. Certainly, further 
research is required to reach a clear conclusion.
In summary, it was identified that DOK7V1 downregula-
tion is associated with poor prognosis of patients with lung 
cancer. The truncations of the DOK7V1 domains appeared 
to have effect on the localization of the protein. DOK7V1 
overexpression reversed the malignant phenotypes of H3122 
cells, including proliferation, migration and adhesion. 
DOK7V1Δ-PH and DOK7V1Δ-PTB were able to eliminate 
the function of DOK7 in adhesion, but not in proliferation 
and migration. The two truncated version retained the 
inhibitory effect of DOK7V1 on AKT activation, but inacti-
vated the enhanced effect of DOK7V1 on FAK and paxillin. 
We hypothesize that DOK7V1 may inhibit proliferation and 
migration via negatively regulating the PI3K/AKT/mTOR 
signaling pathway and increasing adhesion by upregulating 
the FAK/paxillin signaling pathway in lung cancer cells. 
The results of the present study provide a novel basis to 
improve our understanding of the pathogenesis of lung 
cancer.
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